CDKN2A and meningioma: MTAP immunohistochemistry has been demonstrated to be a surrogate marker for homozygous CDKN2A/B deletions and might highlight patients potentially benefiting from novel therapies inhibiting the promotion of DNA damages and mitotic dysfunction in meningioma cells [15].